Skip to main content
News Archive

Vaccitech Appoints Bill Enright as New Chief Executive Officer

By September 3, 2019May 22nd, 2025No Comments

enright-vaccitech-logo.jpgVaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID), announced today that it has appointed Bill Enright as its new Chief Executive Officer (CEO). Mr. Enright succeeds Tom Evans, MD who will make a planned transition to the role of Vaccitech’s Chief Scientific Officer.

{iframe}https://www.b3cnewswire.com/201908271964/vaccitech-appoints-bill-enright-as-new-chief-executive-officer.html{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.